Who is sponsoring NCT03378947?

NCT03378947 is sponsored by Hospices Civils de Lyon.

What drugs are being tested in NCT03378947?

Interventions in NCT03378947: clinical and pathological data EBV-related GZL and DLBCL.

Is NCT03378947 still recruiting?

NCT03378947 is currently completed. Last updated 22 February 2019.

Last reviewed 2019-02-22 · How we verify

NCT03378947

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

EBV-associated Diffuse Large B Cell Lymphoma

Completed Last updated 22 February 2019

What this trial tests

trial testing clinical and pathological data EBV-related GZL and DLBCL in To Characterize and Compare Clinical, Pathological and Molecular Features in 70 participants. Completed in 1 November 2018.

Timeline

1 June 2017

Primary endpoint
15 January 2018

1 November 2018

Quick facts

Lead sponsor	Hospices Civils de Lyon
Status	Completed
Study type	OBSERVATIONAL
Enrollment	70
Start date	1 June 2017
Primary completion	15 January 2018
Estimated completion	1 November 2018
Sites	1 location across France

Drugs / interventions tested

clinical and pathological data EBV-related GZL and DLBCL

Conditions studied

To Characterize and Compare Clinical, Pathological and Molecular Features — all drugs for To Characterize and Compare Clinical, Pathological and Molecular Features →

Sponsor

Hospices Civils de Lyon — full company profile →

Who can join

18 and older, any sex, with To Characterize and Compare Clinical, Pathological and Molecular Features. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The aim of this study is to characterize and compare clinical, pathological (histology, immunophenotype) and molecular features of EBV-related GZL and DLBCL: do they belong to the same entity or to two different subtypes of EBV-related lymphoma ?

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other Hospices Civils de Lyon trials

Trials by the same sponsor.

NCT07569536 — Efficacy of the Alpha 2 Agonist Dexmedetomidine for Sympathetic Deactivation in REfractory Septic Shock · Phase 3 · not yet recruiting
NCT07529314 — Evaluating Interventional Radiology for Cancer Pain Management · NA · not yet recruiting
NCT07273929 — Comparative Study of the Effectiveness of Three Access Routes for Implanting an Electronic Intracardiac Device · Phase 3 · not yet recruiting
NCT07474532 — Attitudes and Beliefs Related to Benzodiazepine Deprescribing · not yet recruiting
NCT07313007 — Assessment of Gut Microbiota-Derived Amino Acid Metabolite Production in Patients With MASLD · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03378947 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Hospices Civils de Lyon
Last refreshed: 22 February 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03378947.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing